Medicare and erythropoietin.
Steinbrook
Robert
R
rsteinbrook@attglobal.net
D000068817:Epoetin Alfa; D004921:Erythropoietin / Q000191:economics* / Q000627:therapeutic use; D018166:Health Care Reform / Q000331:legislation & jurisprudence; D005102:Health Expenditures / Q000639:trends; D006300:Health Services Misuse / Q000191:economics* / Q000331:legislation & jurisprudence; D006454:Hemoglobins; D006801:Humans; D007676:Kidney Failure, Chronic / Q000097:blood / Q000191:economics / Q000628:therapy; D006278:Medicare / Q000191:economics* / Q000331:legislation & jurisprudence; D011994:Recombinant Proteins; D012051:Reimbursement Mechanisms / Q000191:economics / Q000331:legislation & jurisprudence*; D006435:Renal Dialysis / Q000191:economics; D014481:United States
D006454:Hemoglobins; D011994:Recombinant Proteins; D004921:Erythropoietin; D000068817:Epoetin Alfa